Nenad Sarapa1, Margaret R Britto. 1. Johnson & Johnson PRD, Welsh & McKean Roads, Spring House, PA 19477-0776, USA. nsarapa@prdus.jnj.com
Abstract
BACKGROUND: Drug-induced QTc prolongation is becoming increasingly important in oncology since novel therapies result in prolonged survival of cancer patients already predisposed to cardiotoxicity. METHODS: We review the challenges of implementing the ICH E14 guidance in oncology and propose an integrated approach to QTc risk assessment of nonadjuvant anticancer agents (NAAs), with quantitative outcome criteria. RESULTS: We recommend informed use of non-clinical cardiac safety pharmacology results, some degree of robust ECG assessments in early phase studies, a dedicated QTc study in cancer patients conducted at the appropriate time pre-, peri-, or post-approval (with the design and timing agreed upon with regulatory agencies), and ECG monitoring in late-phase studies commensurate with the outcome of previous QTc studies. CONCLUSION: The proposed approach would facilitate risk-benefit assessment for NAAs during clinical development and regulatory review, and enable adequate labeling for safe and effective postmarketing use in cancer patients.
BACKGROUND: Drug-induced QTc prolongation is becoming increasingly important in oncology since novel therapies result in prolonged survival of cancerpatients already predisposed to cardiotoxicity. METHODS: We review the challenges of implementing the ICH E14 guidance in oncology and propose an integrated approach to QTc risk assessment of nonadjuvant anticancer agents (NAAs), with quantitative outcome criteria. RESULTS: We recommend informed use of non-clinical cardiac safety pharmacology results, some degree of robust ECG assessments in early phase studies, a dedicated QTc study in cancerpatients conducted at the appropriate time pre-, peri-, or post-approval (with the design and timing agreed upon with regulatory agencies), and ECG monitoring in late-phase studies commensurate with the outcome of previous QTc studies. CONCLUSION: The proposed approach would facilitate risk-benefit assessment for NAAs during clinical development and regulatory review, and enable adequate labeling for safe and effective postmarketing use in cancerpatients.
Authors: Karthik Venkatakrishnan; William G Kramer; Timothy W Synold; Daniel B Goodman; Evin Sides; Cristina Oliva Journal: Eur J Clin Pharmacol Date: 2012-03-30 Impact factor: 2.953
Authors: Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff Journal: Invest New Drugs Date: 2012-12-16 Impact factor: 3.850
Authors: Eleonora Marostica; Karel Van Ammel; Ard Teisman; Koen Boussery; Jan Van Bocxlaer; Filip De Ridder; David Gallacher; An Vermeulen Journal: J Pharmacokinet Pharmacodyn Date: 2015-08-11 Impact factor: 2.745
Authors: Eleonora Marostica; Karel Van Ammel; Ard Teisman; David Gallacher; Jan Van Bocxlaer; Filip De Ridder; Koen Boussery; An Vermeulen Journal: AAPS J Date: 2016-04-26 Impact factor: 4.009